Thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer: Relationship between mRNA expression and activity

Anticancer Research

Volumn 25, Issue 2 A, 2005, Pages 923-930

  Miyoshi, Takanori ^a   Kondo, Kazuya ^a   Fujino, Haruhiko ^a   Takahashi, Yuji ^a   Sawada, Naruhiko ^a   Sakiyama, Shoji ^a   Tsuyuguchi, Masaru ^a   Kimura, Suguru ^a   Sumitomo, Masayuki ^a   Monden, Yasumasa ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Dihydropyrimidine dehydrogenase (DPD); Non small cell lung cancer; RT PCR; Thymidylate synthase (TS)

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; THYMIDYLATE SYNTHASE; UFT;

ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; DNA SYNTHESIS; DNA SYNTHESIS INHIBITION; ENZYME ACTIVITY; GEL FILTRATION; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOIMMUNOASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THYMIDYLATE SYNTHASE;

EID: 20244368822     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Hoffman PC, Mauer AM and Yokes EE: Lung cancer. Lancet 355: 479-485, 2000.
2. Mountain CF: Revisions in the international system for staging lung cancer. Chest 111: 1710-1717, 1997.
3. Naruke T, Tsuchiya R, Kondo H and Asamura H: Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience. Ann Thorac Surg 71: 1759-1764, 2001.
4. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP and Vansteenkiste J: International Adjuvant Lung Cancer Trial Collaborative Group: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350: 351-60, 2004.
5. Wada H, Hitomi S and Teramatsu T: Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery. J Clin Oncol 14: 1048-1054, 1996.
6. Wada H, Miyahara R, Tanaka F and Hitomi S: Postoperative adjuvant chemotherapy with PVM (cisplatin + vindesin + mitomycin C) and UFT (Uracil + Tegafur) in resected stage I-II NSCLC (non-small cell lung cancer). Eur J Cardiothorac Surg 15: 438-443, 1999.
7. Study Group of Adjuvant Chemotherapy for Lung Cancer (Chubu, Japan): A randomized trial of postoperative adjuvant chemotherapy in non-small cell lung cancer (the second cooperative study). Eur J Surg Oncol 21: 69-77, 1995.
8. Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, Watanabe Y, Wada H, Tsuboi M, Hamajima N and Ohta M: Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy: A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350: 1713-21, 2004.
9. Matsuoka H, Ueo H, Sugimachi K and Akiyoshi T: Preliminary evidence that incorporation of 5-fluorouracil into RNA correlates with antitumor response. Cancer Invest 10: 265-269, 1992.
10. Diasio RB and Harris BE: Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16: 215-237, 1989.
11. Beck A, Etienne MC, Cheradame S, Fischel JL, Formento P, Renee N and Milano G: A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumor sensitivity to fluorouracil. Eur J Cancer 30: 1517-1522, 1994.
12. Kirihara Y, Yamamoto W, Toge T and Nishiyama M: Dihydropyrimidine dehydrogenase, multidrug resistance-associated protein, and thymidylate synthase gene expression levels can predict 5-fluorouracil resistance in human gastrointestinal cancer cells. Int J Oncol 14: 551-556, 1999.
13. Ishikawa Y, Kubota T, Otani Y, Watanabe M, Teramoto T, Kumai K, Takechi T, Okabe H, Fukushima M and Kitajima M: Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: possible predictor for sensitivity to 5-florouracil. Jpn J Cancer Res 91: 105-112, 2000.
14. Ishikawa Y, Kubota T, Otani Y, Watanabe M, Teramoto T, Kumai K, Kitajima M, Takechi T, Okabe H and Fukushima M: Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice. Clin Cancer Res 5: 883-889, 1999.
15. Etienne MC, Cheradame S, Fischel JL, Formento P, Dassonville O, Renee N, Schneider M, Thyss A, Demard F and Milano G: Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 13: 1663-1670, 1995.
16. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB and Danenberg PV: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6: 1322-1327, 2000.
17. Huang CL, Yokomise H, Kobayashi S, Fukushima M, Hitomi S and Wada H: Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy. Int J Oncol 17: 47-54, 2000.
18. Uetake H, Ichikawa W, Takechi T, Fukushima M, Nihei Z and Sugihara K: Relationship between intratumoral dihydropyrimidine dehydrogenase activity and gene expression in human colorectal cancer. Clinical Cancer Res 5: 2836-2839, 1999.
19. Johnson MR, Wang K, Smith JB, Heslin MJ and Diasio RB: Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Anal Biochem 278: 175-184, 2000.
20. World Health Organization: Histological typing of lung tumors. Am J Clin Pathol 77: 123-136, 1982.
21. Ishikawa Y, Kubota T, Otani Y, Watanabe M, Teramoto T, Kumai K, Takechi T, Okabe H, Fukushima M and Kitajima M: Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: possible predictor for sensitivity to 5-fluorouracil. Jpn J Cancer Res 91: 105-112, 2000.
22. Ishikawa Y, Kubota T, Otani Y, Watanabe M, Teramoto T, Kumai K, Takechi T, Okabe H, Fukushima M and Kitajima M: Thymidylate synthetase and dihydropyrimidine dehydrogenase levels in gastric cancer. Anticancer Res 19: 5635-5640, 1999.
23. Takechi T, Okabe H, Fujioka A, Murakami Y and Fukushima M: Relationship between protein levels and gene expression of dihydropyrimidine dehydrogenase in human tumor cells during growth in culture and in nude mice. Jpn J Cancer Res 89: 1144-1153, 1998.
24. Tokunaga K, Nakamura Y, Sakata K, Fujimori K, Ohkubo M, Sawada K and Sakiyama S: Enhanced expression of a glyceraldehyde-3-phosphate dehydrogenase gene in human lung cancers. Cancer Res 47: 5616-5619, 1987.
25. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV and Leichman L: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55: 1407-1412, 1995.
26. Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S, Boswell W, Metzger R, Tan M and Danenberg PV: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15: 3223-3229, 1997.
27. Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Garcia Y, Li J and Leichman L: Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 14: 176-182, 1996.
28. Zhang ZG, Harstrick A and Rustum YM: Mechanisms of resistance to fluoropyrimidines. Semin Oncol 19: 4-9, 1992.
29. Johnston PG, Drake JC, Trepel J and Allegra CJ: Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res 52: 4306-4312, 1992.
30. Peters GJ, van der Wilt CL and van Groeningen CJ: Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase. Eur J Cancer 10: 1408-1411, 1994.
31. Ishikawa Y, Kubota T, Otani Y, Watanabe M, Teramoto T, Kumai K, Kitajima M, Takechi T, Okabe H and Fukushima M: Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice. Clinical Cancer Res 5: 883-889, 1999.
32. Terashima M, Irinoda T, Fujiwara H, Nakaya T, Takagane A, Abe K, Yonezawa H, Oyama K, Inaba T, Saito K, Takechi T and Fukushima M: Role of thymidylate synthase and dihydropyrimidine dehydrogenase on tumor progression and sensitivity to 5-fluorouracil in human gastric cancer. Anticancer Res 22: 761-768, 2002.
33. Mirjolet JF, Barberi-Heyob M, Merlin JL, Marchai S, Etienne MC, Milano G and Bey P: Thymidylate synthase expression and activity: relation to S-phase parameters and 5-fluorouracil sensitivity. Br J Cancer 78: 62-68, 1998.
34. Fischel JL, Formento P, Etienne MC, Spector T, Renee N and Milano G: Dual modulation of 5-fluorouracil cytotoxicity using folinic acid with a dihydropyrimidine dehydrogenase inhibitor. Biochem Pharmacol 53: 1703-1709, 1997.
35. Mori K, Hasegawa M, Nishida M, Toma H, Fukuda M, Kubota T, Nagasue N, Yamana H, Hirakawa-YS Chung K, Ikeda T, Takasaki K, Oka M, Kameyama M, Toi M, Fujii H, Kitamura M, Murai M, Sasaki H, Ozono S, Makuuchi H, Shimada Y, Onishi Y, Aoyagi S, Mizutani K, Ogawa M, Nakao A, Kinoshita H, Tono T, Imamoto H, Nakashima Y and Manabe T: Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. Int J Oncol 17: 33-38, 2000.
36. Otake Y, Tanaka F, Yanagihara K, Hitomi S, Okabe H, Fukushima M and Wada H: Expression of thymidylate synthase in human non-small cell lung cancer. Jpn J Cancer Res 90: 1248-1253, 1999.
37. Huang CL, Yokomise H, Kobayashi S, Fukushima M, Hitomi S and Wada H: Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy. Int J Oncol 17: 47-54, 2000.
38. Higashiyama M, Kodama K, Yokouchi H, Takami K, Fukushima M, Minamigawa K, Takano T and Kobayashi H; Thymidylate synthase and dihydropyrimidine dehydrogenase activities in non-small cell lung cancer tissues: relationship with in vitro sensitivity to 5-fluorouracil. Lung Cancer 34: 407-416, 2001.
39. Fujiwara H, Terashima M, Irinoda T, Takagane A, Abe K, Kashiwaba M, Oyama K, Takahashi M, Maesawa C, Saito K, Takechi T and Fukushima M: Quantitative measurement of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level in gastric cancer by real-time RT-PCR. Jpn J Cancer Res 93: 1342-1350, 2002.
40. Chu E, Koeller DM, Casey JL, Drake JC, Chabner BA, Elwood PC, Zinn S and Allegra CJ: Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase. Proc Natl Acad Sci USA 88: 8977-8981, 1991.
41. Chu E, Voeller D, Koeller DM, Drake JC, Takimoto CH, Maley GF, Maley F and Allegra CJ: Identification of an RNA binding site for human thymidylate synthase. Proc Natl Acad Sci USA 90: 517-521, 1993.
42. Yoshinare K, Kubota T, Watanabe M, Wada N, Nishibori H, Hasegawa H, Kitajima M, Takechi T and Fukushima M: Gene expression in colorectal cancer and in vitro chemosensitivity to 5-fluorouracil: a study of 88 surgical specimens. Cancer Sci 94: 633-638, 2003.
43. Farrugia DC, Ford HE, Cunningham D, Danenberg KD, Danenberg PV, Brabender J, McVicar AD, Aherne GW, Hardcastle A, McCarthy K and Jackman AL: Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed. Clinical Cancer Res 9: 792-801, 2003.